Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply

Sir, We are grateful for the interest in our work [1] shown by Dr Sat ışet al. and agree that it would have been interesting to also compare the effectiveness seen for tofacitinib and other Janus kinase inhibitors to the therapies we included. As they guess in their letter, however, the reason why we did not include data on tofacitinib was that it entered the Swedish market in 2017,after the period included for analysis in our study. We look forward to returning to this topic in the future, when more data have been accumulated.
Source: Rheumatology - Category: Rheumatology Source Type: research